B
300016
vs
S
Shanghai Composite
Over the past 12 months, Beijing Beilu Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +65% compared to the Shanghai Composite's +28% growth.
Stocks Performance
300016 vs Shanghai Composite
Performance Gap
300016 vs Shanghai Composite
Performance By Year
300016 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Beijing Beilu Pharmaceutical Co Ltd
Glance View
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of contrast agents, and central nervous system and hypoglycemic drugs. The company is headquartered in Beijing, Beijing and currently employs 905 full-time employees. The company went IPO on 2009-10-30. The Company’s main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The firm mainly distributes its products in domestic market.
